Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinomaJoong-Won Park, Richard S Finn, Jun Suk Kim, et al.
Liver Cancer|August 18, 2015
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular CarcinomaJean-Luc Raoul, Joong-Won Park, Yoon-Koo Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Botulinum toxin potentiates cancer radiotherapy and chemotherapyRéginald Ansiaux, Christine Baudelet, Greg O Cron, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.
The Lancet. Oncology|February 24, 2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialNaiyer A Rizvi, Julien Mazières, David Planchard, et al.
Pageof 3